Last reviewed · How we verify

Metamizol iv

Hospital General Universitario Elche · Phase 3 active Small molecule

Metamizol is a non-selective cyclooxygenase (COX) inhibitor that reduces prostaglandin synthesis to provide analgesic, antipyretic, and anti-inflammatory effects.

Metamizol is a non-selective cyclooxygenase (COX) inhibitor that reduces prostaglandin synthesis to provide analgesic, antipyretic, and anti-inflammatory effects. Used for Acute pain management (postoperative, trauma, or other acute pain conditions), Fever reduction.

At a glance

Generic nameMetamizol iv
Also known asNolotil
SponsorHospital General Universitario Elche
Drug classNon-selective COX inhibitor / NSAID
TargetCyclooxygenase (COX-1 and COX-2)
ModalitySmall molecule
Therapeutic areaPain Management / Fever
PhasePhase 3

Mechanism of action

Metamizol (dipyrone) inhibits COX enzymes, thereby decreasing prostaglandin production, which mediates pain, fever, and inflammation. It is a prodrug that is rapidly metabolized to active metabolites including 4-methylaminoantipyrine (MAA), which exerts the primary pharmacological effects. The drug has a rapid onset and is commonly used for acute pain and fever management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: